French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)
NCT ID: NCT04328298
Last Updated: 2025-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
5000 participants
OBSERVATIONAL
2019-12-19
2038-12-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real-life Management of Patients Eligible for CAR-T Cell Therapy
NCT06369389
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05422521
Impact of Lymphodepletion Regimen on the Response to CAR T-cells in Patients With With Relapsed/Refractory Large B-cell Lymphoma
NCT06988085
Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma
NCT06890091
Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies
NCT04290000
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
* If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive
Prospective inclusion :
* Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
* Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
* Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019
* If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.
0 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Novartis
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
The Lymphoma Academic Research Organisation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven LE GOUILL, Pr
Role: PRINCIPAL_INVESTIGATOR
Institut Curie
Roch HOUOT, Pr
Role: PRINCIPAL_INVESTIGATOR
CHU Pontchaillou
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'Amiens - Hôpital Sud
Amiens, , France
CHU Angers
Angers, , France
CHRU Besançon - Hôpital Minjoz
Besançon, , France
CHU de Brest - Hôpital du Morvan
Brest, , France
Institut d'Hématologie de Basse Normandie
Caen, , France
CHU d'Estaing
Clermont-Ferrand, , France
APHP - Hôpital Henri Mondor
Créteil, , France
CHU de Dijon
Dijon, , France
CHU de Grenoble
La Tronche, , France
CHRU de Lille - Hôpital Claude Hurriez
Lille, , France
Hôpital Dupuytren
Limoges, , France
Centre Léon Bérard
Lyon, , France
Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP)
Lyon, , France
Hôpital de la Timone
Marseille, , France
Institut Paoli Calmette
Marseille, , France
CHU de Montpellier
Montpellier, , France
CHU de Nantes - Hôtel Dieu
Nantes, , France
CHU de Nice
Nice, , France
APHP - Hôpital Cochin
Paris, , France
APHP - Hôpital La Pitié Salpêtrière
Paris, , France
APHP - Hôpital Necker
Paris, , France
APHP - Hôpital Saint Antoine
Paris, , France
APHP - Hôpital Saint Louis
Paris, , France
APHP - Hôpital Universitaire Robert Debré
Paris, , France
Centre Francois Magendie
Pessac, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Hôpital de la Milétrie - CHU de Poitiers
Poitiers, , France
CHU de Rennes - Hôpital Pontchaillou
Rennes, , France
Centre Henri Becquerel
Rouen, , France
CHU de Rouen Normandie
Rouen, , France
Institut de Cancérologie Hématologie Universitaire de Saint Etienne
Saint-Priest-en-Jarez, , France
ICANS (Institut de Cancérologie Strasbourg Europe)
Strasbourg, , France
Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)
Toulouse, , France
CHU Bretonneau
Tours, , France
CHU Brabois
Vandœuvre-lès-Nancy, , France
Gustave Roussy Cancer Campus
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Adrien CHAUCHET, MD
Role: primary
Aude Collignon, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano de Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B. Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. Blood Adv. 2025 Sep 18:bloodadvances.2025017597. doi: 10.1182/bloodadvances.2025017597. Online ahead of print.
Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros FX, le Bras F, Bories P, Choquet S, Rubio MT, Iacoboni G, O'Reilly M, Casasnovas RO, Bay JO, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024 Aug 6;17(1):61. doi: 10.1186/s13045-024-01579-w.
Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DESCAR-T
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.